Lucid Diagnostics Business Update
Lucid Diagnostics announced progress across three regulatory and reimbursement pathways for its EsoGuard and EsoCheck products, including a Medicare Advisory Panel recommendation to maintain its current payment basis. Additionally, the AMA approved a new Category III CPT code for EsoCheck procedures, and the CDC/NCHS is considering a new ICD-10-CM diagnosis code for positive EsoGuard results. These administrative milestones are intended to streamline billing, coding, and physician reporting for the company's esophageal cancer screening tools.